Aristotle University Of Thessaloniki (AUTH)
Τρόπος δράσης και θεραπευτικό όφελος της ενδοϋαλοειδικής χορήγησης μεσεγχυματικών κυττάρων λιπώδους ιστού και νανοφορέων anti-VEGF σε επαγόμενο ζωικό μοντέλο φλεβικής απόφραξης του αμφιβληστροειδούς
Abstract
dc:descriptionIn recent years, anti-angiogenic therapeutic agents (anti-VEGF) have contributed to the treatment of retinal vein occlusion (RVO) while polymeric nanocarriers for sustained-release ophthalmic drug delivery are emerged rapidly. At the same time, Mesenchymal Stromal Cells-mediated therapies (MSCs) are associated with secretory agents that protect the ganglion cells, limiting eye degeneration. The MEK kinase inhibitor, PD0325901, has been applied to induce RVO following intravitreal administration to rabbits. The aim of the present study is to determine the effect of adipose derived-MSCs (ASCs) combination with nanocarriers of anti-VEGF in a PD0325901-mediated induced animal model of RVO.In an in vitro approach, MEK kinase inhibitor-PD0325901 was used to induce the expression of EPCR (Endothelial Protein C Receptor), a common related to RVO marker, on HUVEC (Human Umbilical Cord Endothelial Cell) culture. Anti-VEGF encapsulated in thiolated chitosan (ThioCHI) nanoparticles, MSCs and a combination of these was applied to the cultures and their effect was monitored. Net nanoparticles of CHI and ThioCHI were prepared by ionic gelation technique while ThioCHI was selected as polymeric matrix for anti-VEGF encapsulation. Their full characterization was followed using Fourier-transform infrared spectroscopy, Differential scanning calorimetry and X-ray diffraction. MSCs were prepared from human adipose tissue liposuction cultured up to five passages. Following 24-hour exposure of HUVEC to PD0325901, the effect of anti-VEGF nanoparticles, MSCs, and a combination of these was assessed by quantifying the secreted EPCR and time-controlled anti-VEGF release. For in vivo experiments, ASCs were isolated from rabbits, expanded and characterized while they genetically modified to secrete the green fluorescence GFP. Twenty-four New Zealand rabbits were divided into the four following groups: Group I ASCs (n = 6), group II ASCs + nanoThioCHI-anti-VEGF (n = 6), group III RVO (n = 6) and group IV control (n = 6). For the RVO induction groups I-III received intravitreal (iv) injections of PD0325901 at a dose volume of 0.1 mL/eye while the control group received BSS only. Twelve days later therapeutic regiments were administered at groups I-II while groups III-IV received BSS. Two weeks later the animals were sacrificed to determine the therapeutic efficacy of all the administered regimens. The retinal lesions were evaluated via detailed ophthalmic examinations, histological analysis of fixed retinal sections, ELISA for secreted cytokines in peripheral blood or vitreous fluid and Q-PCR for the expression of related to the occlusion and inflammatory genes. Very small embryonic like stem cells (VSELs) isolated from animals peripheral blood, as a response to the induced damage, 12 and 36 days after the induction and characterized with alkaline phosphatase staining as well as real-time PCR for the expression of embryonic genes. The modified prepared nanoparticles showed no cytotoxic effect while antibody release was constant for 8 days. The abnormal EPCR levels were statistically significantly reduced after 24- and 48-hours following exposure of the abnormal endothelium either to the anti-VEGF nanoparticles or to MSCs. A combination of both agents was more effective than either agent separately on 24 hours in vitro, followed by simultaneous reduction on VEGF translation levels of abnormal endothelium. Mild retinal edema and hemorrhages, limited retinal detachment and vasculature attenuation were observed in Groups I and II compared with the pathological symptoms of Group III which presented a totally disorganized retinal structure, following of positive immunostaining for neovascularization (FVIII) and related to RVO markers. Important reduction of the high secreted levels of inflammatory cytokines were quantified in Groups I and II vitreous fluid, while the expression of the RVO-related and inflammatory genes has been significantly decreased especially in group II. Positive immunostaining was observed for tissue regeneration markers (ki-67, GFAP) in groups which received one of the proposed therapies. GFP+ ASCs, capable of being differentiated towards neural progenitors, detected in dissociated retina tissues of group II presenting their attachment to damaged area. H&E staining of cell smears revealed very small sized cells with high nucleo-cytoplasmic ratio in RVO-induced animal group only. The positive alkaline phosphatase staining, in combination with the overexpression of the Oct3/4, Nanog and Sox-2 transcription factors confirmed the existence of undifferentiated cells with embryonic like features as a response to damage. A stem cell-based therapy for RVO is proposed, accompanied by sustained and time-controlled release of anti-VEGF, in order to combine the paracrine action of ASCs and the progressive reduction of neovascularization.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gounari, Eleni
- Γούναρη, Ελένη
Subjects
dc:subject × 15- Απόφραξη φλέβας αμφιβληστροειδούς
- Μεσεγχυματικά στρωματικά κύτταρα
- anti-VEGF
- Νανοφορείς
- Χιτοζάνη
- Retinal vein occlusion
- Mesenchymal stromal cells
- Nanocarriers
- Chitosan
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND_4_0
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49502